HSPG-Binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in Murine model

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Lee, Tong Young ^a   Folkman, Judah ^a   Javaherian, Kashi ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARAN SULFATE; LYSYLSERYLVALYLARGINYLGLYCYLLYSYLGLYCYLLYSYLGLYCYLGLUTAMINYLLYSYLARGINYLLYSYLARGINYLLYSYLLYSYLSERYLARGINYLTYROSYLLYSINE; UNCLASSIFIED DRUG; VASCULOTROPIN; PEPTIDE; PROTEOHEPARAN SULFATE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXON; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LIPOSARCOMA; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOLECULAR MIMICRY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SYNTHESIS;

ANIMALIA; MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIPOSARCOMA; MICE; MOLECULAR MIMICRY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955276032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009945     Document Type: Article

References (33)

1. Folkman J (2006) Angiogenesis. Annu Rev Med; 57: 1-18.
2. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-60.
3. Tournaire R, Simonl MP, Noble F, Eichmann A, England P, et al. (2004) A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor. EMBO Rep 5: 262-7.
4. Robinson JC, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Scien 114: 853-65.
5. Hervě MA, Buteau-Lozanoa H, Mourahb S, Calvob F, Perrot-Applanat M(2005) VEGF189 stimulates endothelial cells proliferation and migration in vitro and upregulates the expression of Flk-1/KDR mRNA. Exp Cell Res 309: 24-31.
6. Häcker U, Nybakken K, Perrimon N (2005) Heparan sulphate proteoglycans: the sweet side of development. Nat Rev Mol Cell Biol 6: 530-41.
7. Stringer SE, Gallagher JT (1997) Heparan sulphate. Int J Biochem Cell Biol 29: 709-14.
8. Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparin sulfate. J Biol Chem 273: 24979-82.
9. Cohen T, Gitay-Goren H, Sharon R, Shibuya M, Halaban R, et al. (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 270: 11322-6.
10. Holash J, Davis S, Papadopoulos N, Croll SD, Ho H, et al. (2002) VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-8.
11. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, et al. (1992) The fmslike tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-91.
12. Olander JV, Connolly DT, DeLarco JE (1991) Specific binding of vascular permeability factor to endothelial cells. Biochem Biophys Res Commun 175: 68-76.
13. Terman B, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 787: 1579-86.
14. Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895-8.
15. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and FLT-1, two receptors for vascular endothelial growth factor. J Biol Chem 43: 26988-95.
16. Guo D, Jia Q, Song HY, Warren RS, Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal trans duction that contain SH2 domains. J Biol Chem 270: 6729-33.
17. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, et al. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266: 11947-54.
18. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, et al. (1991) The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806-14.
19. Neufeld G, Cohen T, Gitay-Goren H, Poltorak Z, Tessler S, et al. (1996) Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 15: 153-8.
20. Poltorak Z, Cohen T, Sivan R, Kandelis Y, Spira G, et al. (1997) VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 272: 7151-8.
21. Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, et al. (1996) Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. J Biol Chem 271: 5638-46.
22. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N (1992) Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 267: 26031-7.
23. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317-26.
24. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
25. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE (2006) VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 Lyase. J Biol Chem 281: 1731-40.
26. Lin X, Perrimon N (2003) Developmental roles of heparin sulfate proteoglycans in Drosophila. Glycoconjugate J 19: 363-8.
27. Nybakken K, Perrimon N (2002) Heparan sulfate proteoglycan modulation of developmental signaling in Drosophila. Biochim Biophys Acta 1573: 280-91.
28. Selleck SB (2001) Genetic dissection of proteoglycan function in Drosophila and C. elegans. Semin Cell Dev Biol 12: 127-34.
29. Lin X, Perrimon N (1999) Dally cooperates with Drosophila Frizzled-2 to transduce Wingless signalling. Nature 400: 281-4.
30. Desbordes SC, Sanson B (2003) The glypican Dally-like is required for Hedgehog signalling in the embryonic epidermis of Drosophila. Development 130: 6245-55.
31. Han C, Belenkaya TY, Wang B, Lin X (2004) Drosophila glypicans control the cell-to-cell movement of Hedgehog by a dynamin-independent process. Development 131: 601-11.
32. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501.
33. Brekken RA, Huang X, King SW, Thorpe PE (1998) Vascular Endothelial Growth Factor as a Marker of Tumor Endothelium. Cancer Res 58: 1952-9.